Prana invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference.

PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy

https://www.sec.gov/cgi-bin/viewer?action=view&cik=1131343&accession_number=0001144204-18-047425&xbrl_type=v

Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration

Prana Biotechnology is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases.

1_Prana Biotechnology Investor Presentation_2018-0627 final

Prana Biotechnology is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.

Prana Biotechnology will be presenting at the China Healthcare Investment & Partnering Symposium on Saturday 17 March 2018 at 9.30am China Standard Time.   Please access the webcast via the following link: http://wsw.com/webcast/brileyco20/pran/ The webcast will be archived for 90 days following the presentation.

Dr. David Stamler will be presenting at the China Healthcare Investment & Partnering Symposium on Saturday 17 March 2018 at 9.30am China Standard Time.

Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration